SCHEMBL3583670

SCHEMBL3583670

CON(C)C(=O)C1CCN(c2ccccn2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.51
MALT1 Q9UDY8 2/20 0.51
KDM4E B2RXH2 6/20 0.49
HRH3 Q9Y5N1 2/20 0.48
RIPK1 Q13546 1/20 0.48
HSD17B10 Q99714 6/20 0.48
TSHR P16473 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
AVPR1A P37288 1/20 0.47
CYP46A1 Q9Y6A2 1/20 0.47
ALDH1A1 P00352 5/20 0.47
HPGD P15428 1/20 0.47
CYP2C9 P11712 1/20 0.47
ALOX15 P16050 1/20 0.46
KMT2A Q03164 1/20 0.46
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20729064 0.81 KDM4E (0.67) GPR119MALT1KDM4EHRH3RIPK1
SCHEMBL7660062 0.80 LSS (0.48) GPR119KDM4EHRH3HSD17B10CYP46A1
SCHEMBL10207457 0.80 GPR119 (0.46) GPR119KDM4EKMT2ALMNAMAPT
SCHEMBL13406712 0.80 NOTUM (0.53) GPR119RIPK1CYP2C19CYP3A4CYP46A1
SCHEMBL3586559 0.79 KDM4E (0.52) GPR119KDM4EHSD17B10TSHRCYP2C19
SCHEMBL27722977 0.79 RIPK1 (0.61) GPR119MALT1KDM4ERIPK1HSD17B10
SCHEMBL2274636 0.78 KDM4E (0.66) GPR119MALT1KDM4ERIPK1HSD17B10
SCHEMBL30722454 0.76 KDM4E (0.57) GPR119MALT1KDM4ERIPK1HSD17B10
SCHEMBL30722456 0.76 RIPK1 (0.55) GPR119MALT1KDM4ERIPK1HSD17B10
SCHEMBL18255120 0.76 RIPK1 (0.55) GPR119MALT1KDM4ERIPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772291-B2 Multicyclic compounds and methods of their use LEXICON PHARMACEUTICALS, INC. (US) 2014-07-08 US disclosed
EP-1893212-B1 MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS INC (US) 2013-10-16 EP disclosed
US-20100081691-A1 MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS, INC. (US) 2010-04-01 US disclosed
US-20090306100-A1 METHODS OF TREATING SCHIZOPHRENIA LEXICON PHARMACEUTICALS, INC. 2009-12-10 US disclosed
EP-2089018-A2 METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA Lexicon Pharmaceuticals, Inc. (US) 2009-08-19 EP disclosed
US-20080153811-A1 methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. LEXICON PHARMACEUTICALS, INC. 2008-06-26 US disclosed
WO-2008067121-A2 METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA LEXICON PHARMACEUTICALS, INC. (US) 2008-06-05 WO disclosed
EP-1893212-A2 MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE Lexicon Pharmaceuticals, Inc. (US) 2008-03-05 EP disclosed
WO-2006124897-A2 METHODS AND COMPOSITIONS FOR IMPROVING COGNITION LEXICON GENETICS INCORPORATED (US) 2006-11-23 WO disclosed
WO-2006124748-A2 MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE LEXICON GENETICS INCORPORATED (US) 2006-11-23 WO disclosed
US-20060258691-A1 Methods and compositions for improving cognition LEXICON PHARMACEUTICALS, INC. 2006-11-16 US disclosed
US-20060258672-A1 Multicyclic compounds and methods of their use LEXICON PHARMACEUTICALS, INC. 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081691-A1 MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE GRIN2C, CHAT, COMT GPR119 344/4885MALT1 3084/4885KDM4E 3142/4885
US-20080153811-A1 methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. CHAT, PSEN2, PSEN1 GPR119 1019/4885MALT1 4362/4885KDM4E 2349/4885
US-20090306100-A1 METHODS OF TREATING SCHIZOPHRENIA CHAT, GAP43, GRIN2A GPR119 1901/4885MALT1 3482/4885KDM4E 1625/4885
US-20060258691-A1 Methods and compositions for improving cognition PSEN1, PSEN2, APP GPR119 2230/4885MALT1 4476/4885KDM4E 1641/4885
US-20060258672-A1 Multicyclic compounds and methods of their use GRIN2C, CHAT, COMT GPR119 344/4885MALT1 3084/4885KDM4E 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.